Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 12/20 | 0.54 |
| ▸ | JAK3 | P52333 | 3/20 | 0.53 |
| ▸ | LCK | P06239 | 2/20 | 0.53 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | ITK | Q08881 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL913817 | 0.99 | JAK3 (0.55) | SYKJAK3LCKMAP3K5EGFR | |
| SCHEMBL913759 | 0.97 | MAP3K5 (0.52) | SYKJAK3LCKMAP3K5EGFR | |
| SCHEMBL913635 | 0.93 | SYK (0.48) | SYKJAK3LCKMAP3K5EGFR | |
| SCHEMBL913951 | 0.91 | KCNH2 (0.51) | SYKJAK3LCKMAP3K5EGFR | |
| SCHEMBL913484 | 0.90 | SYK (0.47) | SYKJAK3LCKMAP3K5EGFR | |
| SCHEMBL913989 | 0.90 | SYK (0.47) | SYKJAK3LCKMAP3K5SCN9A | |
| SCHEMBL913554 | 0.88 | SYK (0.45) | SYKJAK3LCKMAP3K5SCN9A | |
| SCHEMBL913828 | 0.85 | SYK (0.46) | SYKJAK3LCKMAP3K5 | |
| SCHEMBL3715143 | 0.84 | MAP3K5 (0.51) | SYKJAK3MAP3K5EGFRITK | |
| SCHEMBL913568 | 0.82 | MAP3K5 (0.49) | SYKJAK3MAP3K5EGFRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | claimed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | claimed |
| US-8853230-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8367689-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2010129802-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137673-A1 | INHIBITORS OF JAK | JAK1, JAK2, JAK3 | SYK 72/4885JAK3 3/4885LCK 62/4885 |
| US-20110005947-A1 | INHIBITORS OF JAK | JAK1, JAK2, JAK3 | SYK 72/4885JAK3 3/4885LCK 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.